MUC1 and cancer: Researchers are exploring the use of various antigens in DC vaccines, including complex tumor lysates, synthetic MHC class I-restricted peptides, and mucin 1 peptide, a key antigen in cancer research [71, 115], WT-1 TAA mRNA is another highly ranked antigen [71, 116].